FindTrial
Sign In

Chemotherapy Regimen

DRUG5 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Concordia Laboratories Inc., Nanfang Hospital, Southern Medical University, Syndax Pharmaceuticals, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiasChemotherapyChemotherapy-induced NeutropeniaHilar CholangiocarcinomaMyelodysplastic SyndromePh-Like

Phase 1

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
RecruitingNCT06226571
Syndax PharmaceuticalsAcute Myeloid Leukemias
Start: 2024-05-21End: 2027-02-01Target: 76Updated: 2026-02-17

Phase 2

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
CompletedNCT00837265
Teva Branded Pharmaceutical Products R&D, Inc.Chemotherapy-induced Neutropenia
Start: 2008-08-21End: 2009-06-26Updated: 2024-04-03

Phase 3

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
TerminatedNCT02082522
Concordia Laboratories Inc.Hilar Cholangiocarcinoma
Start: 2014-11-12End: 2017-01-12Updated: 2019-08-28

Unknown Phase

Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT
NCT02850822
Nanfang Hospital, Southern Medical UniversityChemotherapy, Myelodysplastic Syndrome
Start: 2016-07-31End: 2020-06-30Target: 250Updated: 2017-12-08
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
RecruitingNCT07454226
Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Ph-Like
Start: 2026-05-30End: 2030-03-01Target: 92Updated: 2026-05-13

Related Papers

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708
Blood2025-11-031 citations